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underlying difference in the experience of the condition.
A second pre-test is being conducted using all items
ranked highly across both countries to determine if there
are any differences between countries.
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TRIPTAN THERAPIES
Yalkowsky RB, Malone DC
University of Arizona,Tucson, AZ, USA
OBJECTIVE: To assess the cost-effectiveness of the
various oral triptan tablets currently available in the US
for the acute treatment of migraine headache, and to esti-
mate the prices at which eletriptan and frovatriptan
would need to enter the market in order to be competi-
tive. METHODS: This study uses a decision model 
to evaluate the cost-effectiveness of oral triptan tablets.
Average wholesale prices were obtained from the 2002
Drug Topics Red Book. Efﬁcacy data was derived from
over 65 double-blind, placebo-controlled clinical trials
for almotriptan, eletriptan, frovatriptan, naratriptan,
rizatriptan, sumatriptan, and zolmitriptan. Using patient
reports for pain relief at 1, 2, and 4 hours post-dose, as
well as headache recurrence within 24 hours, and serious
side effects, probability estimates for these parameters
were calculated by weighting each clinical trial estimate
by its sample size. Success was deﬁned as pain relief
within 2 hours without headache recurrence within 24
hours and without a serious side effect. Threshold analy-
ses were conducted to determine the prices of eletriptan
and frovatriptan. RESULTS: All triptans had similar side
effect proﬁles, but varied markedly in price and efﬁcacy.
Almotriptan was the most cost-effective triptan ($35.47
per successful outcome for 12.5mg tablets, $40.92 for
6.25mg), followed by rizatriptan ($44.53 for 10mg,
$48.68 for 5mg) and zolmitriptan (2.5mg $48.88, 5mg
$49.43). All doses of sumatriptan and naratriptan were
greater than $50 per successful outcome. To be competi-
tive with almotriptan, eletriptan would need to be priced
around $9 per tablet for the 80mg dose, and $11 per
tablet for the 40mg dose. Frovatriptan 2.5mg, on the
other hand, needs to be priced at $2 per tablet. CON-
CLUSION: At $10.55 per tablet, almotriptan was the
most cost-effective triptan currently marketed in the US.
The price for eletriptan must be $11 or less to be equally
cost-effective.
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OBJECTIVES: A dynamic multistate model was used to
project the future burden of Chronic Obstructive 
Pulmonary Disease (COPD) in the Netherlands in rela-
tion to trends in demography and smoking. With the help
of the model, different projections can be made that vary
according to assumptions about future developments in
smoking, about demography, and about COPD preva-
lence. METHODS: First, a simple prevalence projection
of COPD was made, applying observed 1994 5-year
prevalence rates on a projection of the population in
2010. That is, the prevalence projection uses prevalence
of for instance the 55- to 59-year-old in 1994 and popu-
lation projections to ﬁnd prevalence of this same age
group 10 years later. Second, a dynamic model that
accounts for age and gender dependent incidence of
COPD and trends in smoking prevalence was used. With
the model we made incidence and smoking based projec-
tions, one assuming that smoking would remain at its
1994 levels and another using a scenario for future
smoking based on observed trends in start and stop rates.
The model basically uses prevalence of the 45- to 49-year-
old in 1994 together with incidence and mortality to
project prevalence of the 55- to 59-year-old 10 years later.
RESULTS: The prevalence projections ﬁnd an increase in
COPD total prevalence of 27%. The model projections
ﬁnd a prevalence increase of 70% and 68%, with the
lower assuming smoking at its 1994 levels. In this speciﬁc
case, the prevalence projections ﬁnd increases in COPD
that are half those projected by the model. CONCLU-
SIONS: The results demonstrate differences between the
extrapolation of prevalence rates using population pro-
jections and more complex projections with a dynamic
model. These differences cannot solely be explained by
trends in smoking prevalence: this is shown by the model
projection with constant smoking prevalence. In this spe-
ciﬁc case, prevalence extrapolations underestimate future
prevalence.
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OBJECTIVE: Hormone replacement therapy (HRT) is
the standard therapy aimed at reducing fracture risk 
in postmenopausal women in Australia, although newer
therapies such as the bisphosphonates, calcitriol and
raloxifene are used in osteoporotic women with radi-
ographically deﬁned fracture due to minimal trauma.
There are many women, however, for whom HRT is inap-
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propriate (eg, those with a history of reproductive cancer
or demonstrated intolerance to HRT), and no publicly
subsidised therapeutic options are available in Australia
for such women. The aim of this study was to assess the
cost-effectiveness of raloxifene in preventing osteoporotic
fractures when HRT is inappropriate. METHODS: A
Markov model was developed to compare raloxifene with
no drug therapy in patients who are unable to use HRT.
Separate analyses were performed for those who are 
intolerant of HRT and those unsuitable for HRT due to
a history of reproductive cancer (with a consequent
greater baseline risk of breast cancer). Relative efﬁcacy
assumptions in the model were taken from randomised
controlled trials and the published literature. Primary out-
comes included vertebral fractures, non-vertebral frac-
tures and breast cancer in a cohort with a low bone
mineral density and an average age of 65 years. The
model ran for a period of 30 years, contained nine dis-
crete states and produced cost per quality-adjusted life-
year (QALY) values. Limited memory was incorporated
into the model by separating each fracture health state
into two states, representing a ﬁrst year and then subse-
quent years after fracture. RESULTS: The incremental
cost per QALY gained with raloxifene compared with no
therapy was $33,539 in those who are intolerant of HRT
and $29,780 per QALY in patients with a history of
reproductive cancer. Extensive sensitivity analyses 
indicated the results remained robust. CONCLUSIONS:
Raloxifene is a cost-effective therapy to reduce fracture
risk in postmenopausal women unsuitable for HRT.
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Continuity is a key treatment success factor to reduce
relapse and hospitalisation rates of schizophrenic
patients. Atypical antipsychotics with daily oral adminis-
tration are associated with improved efﬁcacy, tolerability
and compliance compared with older, conventional neu-
roleptics. Similarly, conventional depots have shown 
to reduce the risk of relapse over oral conventional. The
novel long-acting risperidone, administered intramuscu-
larly once every two weeks, is the ﬁrst long-acting for-
mulation of an atypical antipsychotic. OBJECTIVES: To
assess the cost-effectiveness of long-acting risperidone
versus oral olanzapine and haloperidol decanoate in
recently diagnosed schizophrenic patients. METHODS:
A cost-effectiveness analysis is considered. Main assump-
tion is that compliance improvement, thanks to a long-
acting formulation leads to an increased efﬁcacy. A
decision tree model was built with a time horizon of 
2 years. A French payers perspective was adopted.
Outcome probabilities and cost estimates were based on
published data, and supplemented with expert opinion.
Only direct medical costs were considered. Effectiveness
measures were relapse-free patients and patients main-
tained on the same treatment for 2 years. RESULTS:
76.30% of the patients receiving long-acting risperidone
remained relapse-free, compared with 69.60% with olan-
zapine and 47.70% with haloperidol decanoate. Of the
patients treated with long-acting risperidone, 82.7%
remained successfully on treatment for 2 years, compared
with 74.80% and 57.30% for patients treated with olan-
zapine and haloperidol decanoate respectively. Total
direct cost per patient over 2 years were €13,168 with
risperidone, €13,280 with olanzapine, and €16,910 with
haloperidol decanoate. Long-acting risperidone was the
dominant strategy in each case and remained dominant
strategy in sensitivity analyses. CONCLUSION: The
model indicates that treatment with long-acting risperi-
done reduces relapses, improves continuity of treatment,
and is associated with decreased total direct medical costs
over two years, when compared with oral olanzapine and
haloperidol decanoate.
OD3
STOCHASTIC COST-EFFECTIVENESS ANALYSIS
OF CHRONIC VENOUS LEG ULCERS—THE
CASE OF PROMOGRAN® IN A SWEDISH
HEALTH CARE SETTING
Ghatnekar O1, Hjelmgren J1, Ödegaard K1, Bjellerup M2
1Swedish Institute for Health Economics, Lund, Sweden;
2Helsingborgs Lasarett, Helsingborg, Sweden
OBJECTIVE: To develop a health economic model for
estimating long-term costs and effects of treating chronic
venous leg ulcers (VLU) in Sweden on the basis of a 
randomised clinical trial (RCT) (UK-97-0005 Device +
Adaptic(R) (N:37) vs. Adaptic(R) only (N:36) under
Biﬂex(R) compression bandage). METHOD: Patient data
from a Swedish study including 252 VLU-patients
recruited from a specialised leg ulcer clinic in Malmö
between 1993 and 1997, is used in a Monte Carlo simu-
lation model to estimate individual ulcers’ time-to-healing
(TTH) with conventional treatment. In accordance with
patient data for 80 patients matching the inclusion crite-
ria in the UK-97-0005 Device RCT, we impose a lognor-
mal distribution on the TTH. The effect of UK-97-0005
Device is modeled as the relative efﬁcacy of UK-97-0005
Device versus placebo seen in the clinical trial at the end
of the 12 weeks study period (15%, p > 0.05). Costs are
evaluated from a health care provider perspective (mate-
